RxDoctor Payments Data

Ria Raju

Medical · Philadelphia, PANPI 1306308879

Payments from drug & device makers

$774in general payments, 2019–2025

Across 28 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$205
  • Boston Scientific$96
  • Myriad Genetic Laboratories, Inc.$77
  • Urogen Pharma, Inc.$72
  • Hollister Incorporated$47
  • 180 Medical, Inc.$47
  • plus $229 from 9 others

What the payments were for

  • Food & beverage$774100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sumitomo Pharma America, Inc.8$205
Boston Scientific3$96
Myriad Genetic Laboratories, Inc.2$77
Urogen Pharma, Inc.3$72
Hollister Incorporated1$47
180 Medical, Inc.2$47
Teleflex LLC1$33
Olympus America Inc.1$31
Civco Medical Instruments1$29
Photocure Inc1$27
Telix Pharmaceuticals1$23
Johnson & Johnson1$22
Immunitybio, Inc.1$22
Endo Pharmaceuticals Inc.1$21
Tolmar, Inc.1$20

How this compares

$774 in reported general payments places this provider in the 60th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$26,520
Medicare patients
202
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron178$102,728
GemtesaVibegron37$25,648
Tamsulosin Hcl458$4,679
Oxybutynin Chloride ErOxybutynin Chloride76$1,590
Finasteride148$1,297
Methenamine Hippurate22$921
Estradiol13$746
Dutasteride11$556
Solifenacin Succinate30$554
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$172
Cephalexin12$54

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$205$25,64837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →